Your browser doesn't support javascript.
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19).
Pastick, Katelyn A; Okafor, Elizabeth C; Wang, Fan; Lofgren, Sarah M; Skipper, Caleb P; Nicol, Melanie R; Pullen, Matthew F; Rajasingham, Radha; McDonald, Emily G; Lee, Todd C; Schwartz, Ilan S; Kelly, Lauren E; Lother, Sylvain A; Mitjà, Oriol; Letang, Emili; Abassi, Mahsa; Boulware, David R.
  • Pastick KA; Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
  • Okafor EC; Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
  • Wang F; Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota.
  • Lofgren SM; Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
  • Skipper CP; Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
  • Nicol MR; Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota.
  • Pullen MF; Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
  • Rajasingham R; Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
  • McDonald EG; Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montreal, Canada.
  • Lee TC; Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montreal, Canada.
  • Schwartz IS; Division of Infectious Diseases, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta.
  • Kelly LE; Department of Pediatrics and Child Health, Department of Pharmacology, University of Manitoba, Winnipeg, Canada.
  • Lother SA; Department of Medicine, Sections of Critical Care and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
  • Mitjà O; Fight AIDS and Inf Dis Foundation, Hospital Germans Trias i Pujol, Barcelona, Spain.
  • Letang E; Department of Infectious Diseases, Hospital del Mar/Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
  • Abassi M; ISGlobal, Barcelona Institute for Global Health, Universitat de Barcelona, Barcelona, Spain.
  • Boulware DR; Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Open Forum Infect Dis ; 7(4): ofaa130, 2020 Apr.
Article in English | MEDLINE | ID: covidwho-60353
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews Language: English Journal: Open Forum Infect Dis Year: 2020 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews Language: English Journal: Open Forum Infect Dis Year: 2020 Document Type: Article